Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GABAPENTIN | 600MG | TABLET | Resolved | 2019-03-13 | 2019-07-04 | 78505 |
| APO-GABAPENTIN | 800MG | TABLET | Resolved | 2019-03-27 | 2019-05-21 | 79580 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-01-22 | 2021-01-27 | 132355 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-03-26 | 2021-05-01 | 136400 |
| APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2021-07-05 | 2021-07-08 | 141851 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-07-09 | 2021-08-16 | 142275 |
| APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-28 | 142976 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2021-09-17 | 2021-11-22 | 145837 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-10-08 | 2021-10-29 | 146904 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2022-01-07 | 2022-01-31 | 152310 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2024-08-29 | 2024-10-18 | 236252 |
| APO-GABAPENTIN | 800MG | TABLET | Resolved | 2024-11-21 | 2025-05-23 | 243620 |
| APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2024-12-19 | 2025-01-03 | 246059 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2025-02-20 | 2025-03-21 | 250930 |
| APO-GABAPENTIN | 600MG | TABLET | Resolved | 2025-11-13 | 2025-12-05 | 271853 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2017-03-11 | 2017-03-29 | 604 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-03-11 | 2017-07-13 | 661 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2017-04-07 | 2017-09-15 | 5897 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-06-06 | 2017-08-16 | 12064 |
| APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2017-08-21 | 2017-10-04 | 20000 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |